South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - pessaries - see ingredients - each vaginal tablet contains clotrimazole 100,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - pessaries - see ingredients - each vaginal tablet contains clotrimazole 500,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glenmark pharmaceuticals south africa (pty) ltd - #n/a - not indicated - none

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. esomeprazole magnesium delayed-release capsules delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnes

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - fingolimod hydrochloride (unii: g926ec510t) (fingolimod - unii:3qn8byn5qf) - fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. fingolimod capsules are contraindicated in patients who have: risk summary based on findings from animal studies, fingolimod may cause fetal harm when administered to a pregnant woman. data from prospective reports to the fingolimod pregnancy registry are currently not sufficient to allow for an adequate assessment of the drug-associated risk for birth defects and miscarriage in humans. in oral studies conducted in rats and rabbits, fingolimod demonstrated developmental toxicity, including an increase in malformations (rats) and embryolethality, when given to pregnant animals. in rats, the highest no-effect dose was less than the recommended human dose of 0.5 mg/day on a body surface area (mg/m2 ) basis. the most common fetal visceral malformations in rats were pe

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark generics (europe) ltd - perindopril tert-butylamine indapamide - tablets - 2/0.625 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark generics (europe) ltd - perindopril tert-butylamine indapamide - tablets - 4/1.25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - perindopril tert-butylamine indapamide - tablets - 2/0.625 mg/mg

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - perindopril tert-butylamine indapamide - tablets - 4/1.25 mg/mg

Ireland - English - HPRA (Health Products Regulatory Authority)

glenmark generics (europe) ltd - ropinirole hydrochloride - film coated tablet - 0.25 milligram